HEALTH OF WOMAN. 2017.2(118):103–105; doi 10.15574/HW.2017.118.103

Lakhno I. V.
Kharkiv medical Academy of postgraduate education

The review of existing concepts of the pathogenesis, clinical manifestations, diagnosis and treatment of varicose veins of the lower limbs and pelvic organs in women was performed. A significant negative impact of hormone-induced phlebopathy and chronic pelvic pain syndrome of circulatory genesis on the quality of life of gynecological patients was shown. The conclusion about the expediency of usage taking into account the possible benefits of the drug Venovital to treat women with varicose veins disease was done.

Key words: varicose veins disease, treatment, Venovital.

REFERENCES

1. Lahno IV. 2009. Gormon-indutsirovannaya flebopatiya: fokus na fleboprotektornoy terapii u patsientok, ispolzuyuschih kombinirovannyie oralnyie kontratseptivyi. Consilium medicum Ukraina. 3;6: 14–16.

2. Agus GB. 2011. Medical treatment of chronic venous disease: evolution or involution? Minerva Cardioangiol. 59;3: 285–298.

3. Biasi G, Di Sabatino V, Ghizzani A, Galeazzi M. 2014. Chronic pelvic pain: comorbidity between chronic musculoskeletal pain and vulvodynia. Reumatismo. 66;1: 87–91. https://doi.org/10.4081/reumatismo.2014.768; PMid:24938200

4. Bogucka-Kocka A, Wozniak M, Feldo M et al. 2013. Diosmin-isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use. Nat Prod Commun. 8;4: 545–550. PMid:23738475

5. de Souza Md, Cyrino FZ, Mayall MR et al. 2016. Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon® 500 mg) on microvascular damage elicited by sclerotherapy. Phlebology. 31;1: 50–56. https://doi.org/10.1177/0268355514564414; PMid:25514922

6. Gohel MS, Davies AH. 2009. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr. Vasc. Pharmacol. 7;3: 303–308. https://doi.org/10.2174/157016109788340758; PMid:19601855

7. González OA. 2017. Sulodexide and phlebotonics in the treatment of venous ulcer. Int Angiol. 36;1: 82–87.

8. Karetová D. 2015. Chronic venous disorders – necessity of specific differentiation to determination of the best medical treatment. Vnitr Lek. 61;9: 762–764. PMid:26790171

9. Koo S, Fan CM. 2014. Pelvic congestion syndrome and pelvic varicosities. Tech Vasc Interv Radiol. 17;2:90–95. https://doi.org/10.1053/j.tvir.2014.02.005; PMid:24840963

10. Maruszynski M, Staszkiewicz W, Andziak P. 2007. A double blind, randomized study of semisynthetic diosmin, and purified, micronized flavonoid fraction (diosmin and hesperidin), on symptoms of chronic venous insufficiency of lower limb – a four week observation. Przeglad flebologiczny. 8: 978–985.

11. Moormann O, Gralow I. 2014. Chronic pelvic pain. Schmerz. 28;3: 305–310. https://doi.org/10.1007/s00482-014-1409-3; PMid:24903045

12. Pietrzycka A, Kуzka M, Urbanek T et al. 2015. Effect of Micronized Purified Flavonoid Fraction Therapy on Endothelin-1 and TNF-a Levels in Relation to Antioxidant Enzyme Balance in the Peripheral Blood of Women with Varicose Veins. Curr Vasc Pharmacol. 13;6:801–808. https://doi.org/10.2174/1570161113666150827124714

13. Toledo RR, Santos MЕ, Schnaider TB. 2017. Effect of Pycnogenol on the Healing of Venous Ulcers. Ann Vasc Surg. 38: 212–219. https://doi.org/10.1016/j.avsg.2016.04.014; PMid:27521821

14. Zielinska-Przyjemska M, Ignatowicz E. 2008. Citrus fruit flavonoids influence on neutrophil apoptosis and oxidative metabolism. Phytother Res. 22;12: 1557–1562. https://doi.org/10.1002/ptr.2449; PMid:18803250

15. Zhang F, Man X, Yu H et al. 2015. Synergistic protective effects of escin and low-dose glucocorticoids against vascular endothelial growth factor-induced blood-retinal barrier breakdown in retinal pigment epithelial and umbilical vein endothelial cells. Mol Med Rep. 11;2: 1372–1377. PMid:25370688